Results 101 to 110 of about 7,614,121 (392)

Market Structure and Drug Innovation [PDF]

An explosion of knowledge and a growing array of tools and technologies have transformed modern drug R&D, while its cost has risen by a sizable amount.
Pammolli, Fabio, Riccaboni, Massimo
core   +1 more source

β‐TrCP overexpression enhances cisplatin sensitivity by depleting BRCA1

Molecular Oncology, EarlyView.
Low levels of β‐TrCP (Panel A) allow the accumulation of BRCA1 and CtIP, which facilitate the repair of cisplatin‐induced DNA damage via homologous recombination (HR) and promote tumor cell survival. In contrast, high β‐TrCP expression (Panel B) leads to BRCA1 and CtIP degradation, impairing HR repair, resulting in persistent DNA damage and apoptosis ...
Rocío Jiménez‐Guerrero, Alejandro Belmonte‐Fernández, Mónica González‐Moreno, Laura Rodríguez‐Cordero, Begoña Pérez‐Valderrama, Joaquín Herrero‐Ruíz, Francisco Romero, Carmen Sáez, Miguel Á. Japón   +8 more
wiley   +1 more source

Liaisons Dangereuses? new drugs, physicians and the drug industry. [PDF]

Bone Marrow Transplant, 2021
Gale RP, Lazarus HM.
europepmc   +1 more source

The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules

Molecules, 2019
The Food and Drug Administration approved 59 new drugs (42 New Chemical Entities and 17 Biologics) during 2018. This number breaks the previous record of 53 approved by the same organization in 1996.
Beatriz G de la Torre, F. Albericio
semanticscholar   +1 more source

The Determinants of Pharmaceutical R&D Expenditures: Evidence from Japan [PDF]

During the past 20 years, the world pharmaceutical industry has experienced a dramatic increase in R&D intensity. We apply and extend a model developed by Grabowski and Vernon (2000) with a pooled data sample of the 15 publicly listed Japanese drug firms
Mahlich, Jörg C., Roediger-Schluga, Thomas   +1 more
core  

Olaparib synergy screen reveals Exemestane induces replication stress in triple‐negative breast cancer

Molecular Oncology, EarlyView.
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh, Liping Su, Suet Lin Chia, Xiaohe Tian, Haslina Ahmad, Martin R. Gill   +5 more
wiley   +1 more source

Articulação da indústria farmacêutica brasileira com o exterior: há evidências de especialização regressiva?

Cadernos de Saúde Pública
Em caráter exploratório, o objetivo deste artigo é investigar se há indícios de especialização regressiva no padrão de comércio exterior da indústria farmacêutica brasileira, a partir da liberalização comercial dos anos 1990.
Fábio Batista Mota, José Eduardo Cassiolato, Carlos Augusto Grabois Gadelha   +2 more
doaj  

Optimization of Protein-Protein Interaction Measurements for Drug Discovery Using AFM Force Spectroscopy [PDF]

, 2019
Increasingly targeted in drug discovery, protein-protein interactions challenge current high throughput screening technologies in the pharmaceutical industry.
Basson, Marc D., Chen, Liangliang, Dong, Lixin, Hou, Jing, Jiao, Nian-Dong, Liu, Lianqing, Monemianesfahani, Amir, Sun, Zhiyong, Xi, Ning, Yang, Ruiguo, Yang, Yongliang, Zeng, Bixi   +11 more
core   +1 more source

RKIP overexpression reduces lung adenocarcinoma aggressiveness and sensitizes cells to EGFR‐targeted therapies

Molecular Oncology, EarlyView.
RKIP, a metastasis suppressor protein, modulates key oncogenic pathways in lung adenocarcinoma. In silico analyses linked low RKIP expression to poor survival. Functional studies revealed RKIP overexpression reduces tumor aggressiveness and enhances sensitivity to EGFR‐targeted therapies, while its loss promotes resistance.
Ana Raquel‐Cunha, Joana Pinheiro, Rui F. Marques, Patrícia Fontão, Diana Cardoso‐Carneiro, Adriana Mendes, Izabela N. F. Gomes, Ana Carolina Laus, Renato J. da Silva‐Oliveira, Rui Manuel Reis, Olga Martinho   +10 more
wiley   +1 more source

Contribuições do modelo Fatores Críticos de Sucesso para análise da gestão de Parcerias para o Desenvolvimento Produtivo de um laboratório oficial

Cadernos de Saúde Pública
Resumo: A Parceria para o Desenvolvimento Produtivo (PDP) é uma das medidas usada pelo Estado brasileiro para incentivar a política de inovação, ampliar o acesso da população a medicamentos estratégicos e reduzir a dependência tecnológica do país, por ...
Daniela Rangel Affonso Fernandes, Sheyla Maria Lemos Lima, Roberto Pierre Chagnon   +2 more
doaj   +1 more source